Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ascletis Signs Up with CR Pharma to Distribute Novel HCV Treatment

publication date: Jun 26, 2018

Ascletis BioScience of Beijing has signed a strategic cooperation agreement with CR Pharmaceutical Commercial Group to launch Ganovo® (danoprevir). Ganovo, a direct-acting anti-viral agent, is Ascletis' first approved product and the first direct-acting anti-viral HCV treatment approved in China. The approval was announced earlier this month. In May, Ascletis became the first China pharma to apply for a Hong Kong IPO under new rules allowing pre-revenue pharmas to stage their initial public offerings on the exchange. The IPO is expected later this year. More details....

Stock Symbol: (HK:3320)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here